Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia
2024-513002-60-00Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Jul 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) and coronavirus disease 2019 (COVID-19) comparing Trimodulin with Placebo (2 arms). Primary endpoint: Composite primary endpoint: deterioration / mortality rate. Started Jul 2024; status: completed.
02
Drugs
Pentaglobin
03
Conditions
community-acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-513002-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513002-60-00.